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Abstract
Objective: Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal hyperplasia (CAH) from a
fatal to a chronic lifelong disease. Long-term treatment, in particular the chronic (over-)treatment with glucocorticoids, may
have an adverse effect on the cardiovascular risk profile in adult CAH patients. The objective of this study was to evaluate
the cardiovascular risk profile of adult CAH patients.
Design: Case-control study.
Patients and Measurements: In this case-control study the cardiovascular risk profile of 27 adult CAH patients and 27
controls, matched for age, sex and body mass index was evaluated by measuring ambulatory 24-hour blood pressure,
insulin sensitivity (HOMA-IR), lipid profiles, albuminuria and circulating cardiovascular risk markers (PAI-1, tPA, uPA, tPA/PAI-
1 complex, hsCRP, adiponectin, IL-6, IL-18 and leptin).
Results: 24-Hour systolic (126.3 mmHg615.5 vs 124.8 mmHg615.1 in controls, P= 0.019) and diastolic (76.4 mmHg612.7
vs 73.5 mmHg612.4 in controls, P,0.001) blood pressure was significantly elevated in CAH patients compared to the
control population. CAH patients had higher HDL cholesterol levels (P,0.01), lower hsCRP levels (P= 0.03) and there was a
trend toward elevated adiponectin levels compared to controls. Other cardiovascular risk factors were similar in both
groups.
Conclusion: Adult CAH patients have higher ambulatory blood pressure compared to healthy matched controls. Other
cardiovascular risk markers did not differ, while HDL-cholesterol, hsCRP and adiponectin levels tended to be more favorable.
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Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive
disorder of adrenal steroidogenesis. In 95% of cases it is caused by
21-hydroxylase deficiency.[1] Deficiency of 21-hydroxylase results
in impaired adrenal synthesis of cortisol and often also of
aldosterone leading to increased secretion of ACTH by the
pituitary gland, adrenal hyperplasia, and excessive production of
adrenal androgens. Current treatment of CAH consists of
administration of glucocorticoids and, if necessary, of mineralo-
corticoids to prevent adrenal crises and to suppress the abnormal
secretion of adrenal androgens. Patients with CAH are at risk of
developing signs and symptoms of Cushing’s syndrome, as the
therapeutic range of treatment with glucocorticoids is narrow and
slightly supraphysiological doses of glucocorticoids are need-
ed.[1,2] Cushing’s syndrome is associated with insulin resistance
and cardiovascular morbidity.[3] Therefore, patients with CAH
may develop an adverse cardiovascular risk profile, which is of
increasing clinical importance as nowadays nearly all CAH
patients reach adulthood.
A recent Swedish population study described an increased risk
ratio for all-cause mortality of 2.19 (confidence interval 1.91–2.51)
for men and 2.86 (confidence interval 2.54–3.20) for women
treated with glucocorticoids in Addison’s disease. [4] The excess
mortality in both males and females was mainly attributable to
cardiovascular disease (risk ratio (RR) for cardiovascular death in
men 1.97 (confidence interval 1.61–2.39); RR in women 2.31
(confidence interval 1.94–2.74)). The increased cardiovascular
mortality in Addison’s patients is most likely caused by excess
glucocorticoid exposure. CAH patients are commonly treated with
significantly higher doses of glucocorticoids than Addison’s
patients, already starting directly after birth. Therefore, evaluating
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24204
the cardiovascular risk profile in CAH patients is of importance,
with the oldest CAH patients now being in their sixties.
So far, few studies have focused on cardiovascular risk in CAH
patients. An elevated body mass, an increased fat mass and insulin
resistance have been described in adult and pediatric CAH
patients.[5] Blood pressure has been studied mainly in pediatric
and young adult CAH patients and showed a tendency towards
high blood pressure in some, but not all, studies.[5] Lipid profiles
in adult CAH patients did not show unfavorable changes.[5]
We hypothesized that adult CAH patients are at risk to develop
an unfavorable cardiovascular risk profile due to lifelong treatment
with glucocorticoids. As described above, results of prior studies
concerning the cardiovascular risk profile in CAH patients are
inconclusive. Furthermore, most studies were performed in small
patient groups, or mainly in pediatric patients or without a proper
control group. As adult CAH patients tend to become obese,
especially proper matching for body mass is warranted. More
recent markers for cardiovascular risk, like plasminogen activator
inhibitor type 1 (PAI-1), tissue-type plasminogen activator (tPA),
urokinase-type plasminogen activator (uPA), tPA/PAI-1 complex
and high sensitive CRP (hsCRP), have not been studied before in
CAH patients. Therefore, the aim of this study was to evaluate
insulin sensitivity, blood pressure, albuminuria, lipid profile, and
other circulating cardiovascular risk markers in adult CAH
patients and to compare to the cardiovascular risk profile of
carefully matched control subjects.
Materials and Methods
Patients
Adult patients with proven congenital adrenal hyperplasia were
included in this study. Inclusion criteria for patients were
biochemically and genetically proven CAH and stable glucocorti-
coid and mineralocorticoid therapy for 3 months. For each
individual patient a healthy, age-, sex- and body mass index
(BMI)-matched control was recruited by advertisements. Inclusion
criteria for control subjects were an unremarkable medical history
and at present no evidence of disease, no medication (except for oral
contraceptives) and Caucasian race. Exclusion criteria for patients
and control subjects were age ,18 years and inability to give
informed consent. All patients were fully informed about the aim
and design of the study and all the methods involved. They
consented with the study protocol according to the recommenda-
tions of the medical ethical committee of the Radboud University
Nijmegen Medical Centre.
Methods
Each participant visited the hospital on two consecutive days. On
the first day, participants visited the hospital in the morning after
abstinence of caffeine containing substances and an overnight (10-
hour) fast. All participants received a physical examination including
anthropometric measurements. Blood was drawn to assess fasting
glucose, insulin, HDL cholesterol, LDL cholesterol, total cholesterol,
triglycerides, and several circulating cardiovascular risk markers, like
PAI-1, tPA, uPA, tPA/PAI-1 complex, hsCRP, adiponectin, IL-6,
IL-18 and leptin. Plasma concentrations of total adiponectin, IL-6
and IL-18, hsCRP and leptin were determined using ELISAs (R&D
Systems, Minneapolis, MN). ELISAs, developed by our department,
were used for assessment of components of the plasminogen
activation system (uPA, tPA and PAI-1) and its complexes
(tPA:PAI-1).[6,7] PAI-1/tPA ratios were calculated. Insulin resistance
(IR) was estimated using the homeostasis model assessment (HOMA)
method [IR= insulin (mmol/ml)6glucose (mmol/l)/22.5].[8] Office
blood pressure was measured using a Dinamap Vital Signs Monitor.
Blood pressure was measured twice supine and once in upright
position. Mean supine office blood pressure was calculated.
Subsequently, ambulatory blood pressure was monitored for
24 hours (SpaceLabs model 90207). On the second day, participants
returned to the hospital for disconnection of the ambulatory blood
pressure monitoring device.
Statistics
For calculations and statistical analyses, the SPSS personal
computer software package was used and P,0.05 was considered
statistically significant. Abnormally distributed data were log-
transformed. Differences between CAH patients and controls were
statistically tested using unpaired Student’s t-test or the Mann-
Whitney U-test, as appropriate. Results are expressed as mean 6
SEM, unless otherwise indicated.
Results
A total of 27 patients were included in this study. 20 patients
had the salt-wasting type of CAH, 6 patients were simple virilizers
and 1 patient had a non-classic type of CAH. The control group
was well matched for age, sex and BMI. Key parameters of the
selected population were similar to the whole population of adult
CAH patients treated in our medical centre. At the time of the
investigation twenty-three patients were treated with hydrocorti-
sone as the only glucocorticoid. One patient was treated with
dexamethasone only, one patient was treated with cortisone
acetate only and two patients received a combination of
dexamethasone and hydrocortisone. Glucocorticoid doses were
converted into hydrocortisone equivalents using anti-inflammatory
equivalents (hydrocortisone 30 mg= cortisone acetate 37.5 mg=
dexamethasone 0.75 mg). Hydrocortisone equivalents are also
presented as mg/m2. Five patients had plasma renin levels
,5 mU/l, consistent with overtreatment. Characteristics of our
study population, including current daily hydrocortisone and
fludrocortisone dosage, are shown in table 1.
Blood pressure profiles
Office blood pressure measurements during hospital visit
showed no significant differences in supine and upright systolic
and diastolic blood pressure between CAH patients and controls.
Supine and upright heart rates during hospital visit were not
different in CAH patients compared to controls (table 1).
Mean 24-hour systolic (mean 6 SD, 126.3615.5 mmHg vs
124.8615.1 mmHg, P=0.019) and diastolic (76.4612.7 mmHg
vs 73.5612.4 mmHg, P,0.001) blood pressure was significantly
elevated in CAH patients compared to the control population.
Mean arterial pressure (MAP, 92.7612.9 mmHg vs 90.0612.3
mmHg in controls, P,0.001) and heart rate (77.1 bpm617.9 vs
74.2 bpm615.5 in controls, P,0.001) also showed significantly
higher levels in CAH patients than in controls. Measured blood
pressure values and differences between day- and nighttime are
shown in figure 1.
When analyzed separately for day and night, systolic blood
pressure was not significantly elevated during the day (08.00 h to
22.00 h) nor during the night (22.00 h to 08.00 h), but diastolic
blood pressure was elevated both during day- (P,0.001) and
nighttime (P=0.001) in CAH patients compared to controls. CAH
patients thus had a similar blood pressure dip during the night as
compared to controls.
Urinary cardiovascular risk markers
Albumin excretion was comparable in CAH patients and
controls (data not shown).
Cardiovascular Risk in CAH
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Lipid profile
HDL cholesterol concentration was higher in CAH patients
compared to controls. No significant differences in total choles-
terol, LDL cholesterol and triglycerides between CAH patients
and controls were observed (Table 2).
Insulin sensitivity
Fasting plasma glucose levels did not differ between CAH
patients and controls (4.660.6 vs 4.860.6 mmol/L, P=not
significant). Insulin levels also were comparable in CAH patients
and controls (9.464.6 vs 10.164.8 pmol/L, P=not significant), as
was calculated HOMA-IR (2.061.2 vs 2.261.0, P=not signifi-
cant).
Circulating cardiovascular risk markers
A trend toward elevated adiponectin levels in CAH patients
compared to controls was observed (Table 3). Significantly lower
hsCRP levels were found in CAH patients compared to controls
(P=0.03). PAI-1, uPA, tPA, tPA/PA1-complex, PAI-1/tPA ratio,
IL-6, IL-18 and leptin levels were not significantly different in
CAH patients and controls (Table 2).
Clinical characteristics
Average BMI was high in CAH patients (27.264.6 kg/m2).
Waist and hip circumference and waist/hip ratio were not
different in CAH patients compared to controls (data shown in
table 1). It was not possible to evaluate BMI as an individual
cardiovascular risk marker because controls were matched for
BMI in our study.
Discussion
The present study shows that the cardiovascular risk profile of
adult CAH patients is relatively unaffected compared to a carefully
BMI, sex and age matched control group; only slightly elevated
24-hour blood pressure levels were found.
Our finding of an elevated 24-hour blood pressure profile in
adult CAH patients was not reported in earlier studies in adult
CAH patients.[9,10] However, studies in young adult and
pediatric CAH patients did show a tendency towards hyperten-
sion.[5] Elevated blood pressure in CAH patients may be caused
both by glucocorticoid and mineralocorticoid therapy, as gluco-
corticoid as well as mineralocorticoid excess is known to result in
high blood pressure.[11,12] As 24-hour blood pressure is only
slightly elevated it is hard to predict the clinical importance of this
finding for the individual patient. Therefore, it is uncertain if the
elevation in 24-hour blood pressure profile found in our
population will lead to an increased cardiovascular mortality.
The increase was found in ambulatory blood pressure, not in office
blood pressure, suggesting that a given office blood pressure in a
CAH patient may reflect slightly higher 24 h hypertensive burden
and thus more risk compared to control subjects.
The finding of a tendency toward elevated adiponectin levels in
adult CAH patients is in line with the study by Vo¨lkl et al. who
reported significantly elevated adiponectin levels in 51 children
and adolescents with CAH.[13] Adiponectin has insulin sensitizing
and anti-inflammatory properties and high adiponectin levels are
associated with lower risk of myocardial infarction and a reduced
risk of type 2 diabetes.[14,15] Adiponectin levels are known to be
decreased in obesity, insulin resistance and type 2 diabetes,[16]
and administration of glucocorticoids and androgens have been
shown to decrease adiponectin levels.[17,18] The higher adipo-
nectin level found in CAH patients treated with glucocorticoids is
thus somewhat surprising. With respect to their cardiovascular risk
profile, elevated adiponectin levels might have a beneficial effect
concerning the development of type 2 diabetes and myocardial
infarction.
In contrast to earlier studies,[5] including one of our own,[19]
our adult CAH patients were not insulin resistant when evaluated
by the HOMA-IR method. The probable explanation for this
finding is the careful matching in BMI. Alternatively, the HOMA
method may not have been sensitive enough to detect differences
in our population. The lipid profile of adult CAH-patients showed
no unfavorable changes. This finding is in line with earlier studies
evaluating lipid profiles.[5] In the present study we found
significantly elevated HDL-cholesterol levels; Falhammer et al
showed a tendency towards higher HDL-cholesterol in female
CAH patients 30 years of age or older.[9]
To our knowledge hsCRP levels have not been studied before in
CAH patients. The trend towards lower hsCRP levels in CAH
patients may be explained by the chronic treatment with
glucocorticoids. It is well known that glucocorticoids have anti-
inflammatory effects, but data on the direct effect of glucocorticoid
treatment on CRP levels are lacking.[20]
Most studies evaluating cardiovascular risk factors in CAH
patients have focussed on one or several risk factors. Recently, the
CaHASE study evaluated the health status, including cardiovas-
cular and metabolic risk, in a large British cohort of 199 adult
CAH patients due to 21-hydroxylase deficiency. [21] Results
Table 1. Characteristics of the study population.
Patients
(n =27)
Controls
(n=27)
Gender (M/F) 12/15 12/15
Age (years) 30.268.0 32.5611.7
Height (m) 1.6760.10 1.7560.09#
Weight (kg) 75.4613.1 83.3614.5#
BMI (kg/m2) 27.264.6 27.364.8
Waist circumference (cm) 86.9611.5 88.3612.0
Hip circumference (cm) 101.669.7 103.969.4
Waist/hip ratio 0.8660.08 0.8560.08
Office systolic blood pressure (mmHg)
Supine 133612 133612
Upright 128613 131612
Office diastolic blood pressure (mmHg)
Supine 83610 80610
Upright 91610 90610
Office heart rate (bpm)
Supine 67613 66611
Upright 78614 79614
Daily hydrocortisone dosage (mg) 23.468.0 -
Daily hydrocortisone dosage (mg/m2)* 12.664.48 -
Daily fludrocortisone dosage (mg)** 0.1160.06 -
Plasma renin level (mE/l) 34.9669.9 -
Mean values61 SD are given.
M=male; F = female; bpm=beats per minute,
#P,0.05,
*Glucocorticoid doses were converted into hydrocortisone equivalents using
anti-inflammatory equivalents,
**25 patients were treated with fludrocortisone.
doi:10.1371/journal.pone.0024204.t001
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were compared to Health Survey for England data. Similar to
our study they showed elevated diastolic but not systolic blood
pressure. Differences in blood pressure results between our study
and the CaHASE study may be explained by the fact that in the
CaHASE study no 24-hour ambulatory blood pressure measure-
ment was performed and that the results were compared to
reference values of the general population. Furthermore they
report high frequencies of obesity (41%), hypercholesterolemia
(46%), insulin resistance (29%) and osteopenia (40%) compared
to reference values. As data in the CaHASE study are only
compared to age- and sex-matched reference data it is hard to
compare their results with those obtained in our study, using an
age-, sex- and BMI-matched cohort, as increased BMI plays an
important role in both cardiovascular and metabolic risk.
Falhammar et al. recently evaluated cardiovascular and meta-
bolic risk in adult male CAH patients. [22] Their findings are
partly in agreement with ours: increased fat mass and similar lipid
profiles, but no increased blood pressure, which may be due to
the small (sub) sample sets.
Our study had limitations. We have used the HOMA-IR
method to evaluate insulin sensitivity instead of the gold standard,
the euglycemic clamp. Furthermore, the fact that we have chosen
to use a BMI-matched control group, precludes us to evaluate the
Table 2. Lipid profile in adult CAH patients and healthy,
matched controls.
CAH patients
(n =27)
Controls
(n =27) P-value
Total cholesterol (mmol/l) 4.661.0 4.261.0 0.22
Triglycerides (mmol/l) 1.060.6 1.060.6 0.93
HDL cholesterol (mmol/l) 1.460.3 1.160.2 ,0.01
LDL cholesterol (mmol/l) 2.860.7 2.760.9 0.87
Mean values61 SD are given.
doi:10.1371/journal.pone.0024204.t002
Figure 1. Mean 24-hour ambulatory blood pressure measurements (±1 SD) in CAH patients (open squares) and matched controls
(closed squares).
doi:10.1371/journal.pone.0024204.g001
Table 3. Circulating cardiovascular risk markers in adult CAH
patients and healthy, matched controls.
CAH patients
(n =27)
Controls
(n=27) P-value
IL-18 (pg/mL) 57624 53626 0.56
IL-6 (pg/mL) 1.3161.50 1.3761.26 0.89
Adiponectin(ug/mL) 4.1763.03 2.9361.33 0.06
Leptin (ng/mL) 24620 (n = 26) 24618 0.92
hsCRP (mg/L)* 1.0661.49 1.7961.83 0.03
uPA (ng/mL) 0.9960.52 0.9260.54 0.63
PAI-1 (ng/mL) 55629 51619 0.51
tPA (ng/mL) 4.8662.13 6.0163.74 0.17
tPA-PAI-1 complex
(ng/mL)
6.9563.67 9.1165.52 0.10
PAI-1/tPA ratio 12.5367.72 10.1964.23 0.17
Mean values61 SD are given.
*As hsCRP values were not distributed normally, we have calculated log(CRP)
values.
doi:10.1371/journal.pone.0024204.t003
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role of obesity as a cardiovascular risk factor in CAH patients. This
may be relevant as the CAH group was on average overweight.
Evaluation of the cardiovascular risk profile depends on the
evaluated markers. In this study we did not evaluate endothelial
dysfunction, endothelial vasodilative capacity and the endothelial
response to glucocorticoid and mineralocorticoids. As we did not
control for the effects of environmental and physiological factors
like stress and health behaviour we could not evaluate the role of
these factors on blood pressure levels and other cardiovascular risk
factors.
In summary, this study shows that adult CAH patients have an
elevated ambulatory blood pressure, but otherwise a normal
cardiovascular risk profile compared to healthy BMI, age and sex
matched controls. One may speculate that elevated adiponectin
and HDL-cholesterol and decreased hsCRP levels may even have
some protective effect on the development of cardiovascular
disease in these patients.
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